Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Ulrich Ronellenfitsch(University of Mannheim), Katrin Jensen(Heidelberg University), Tracy Slanger(Institute for Quality and Efficiency in Health Care), Meinhard Kieser(Heidelberg University), Matthias Schwarzbach(Klinikum Frankfurt Höchst), Peter Kienle(Heidelberg University), Ralf‐Dieter Hofheinz(Goethe University Frankfurt)
Cochrane Database of Systematic Reviews
May 28, 2013
10.1002/14651858.cd008107.pub2
Cited by 178

Related Papers

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2015|723
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|536